Company Overview - Bicara Therapeutics focuses on developing bifunctional antibody-based therapies for solid tumors, with its lead product candidate being ficerafusp alfa, which targets EGFR and TGF-beta pathways [1][7]. Insider Activity - Claire Mazumdar, CEO of Bicara Therapeutics, executed a sale of 8,234 shares under a pre-arranged Rule 10b5-1 plan, which is a strategy used by insiders to avoid accusations of insider trading [3][9]. - This transaction represents the smallest percentage of holdings sold in a single trade by Mazumdar, amounting to 2.37% of her total holdings [2]. Transaction Details - The shares were sold between March 4 and March 6, 2026, at prices ranging from $18.25 to $18.47 per share, with the company's stock having increased by 30.60% over the past year as of March 6, 2026 [3][10]. - Following the transaction, Mazumdar's direct common stock holdings decreased to 339,392 shares, but she retains an additional 227,873 exercisable options, indicating a significant potential equity stake in the company [4][6]. Financial Performance - Bicara Therapeutics reported a net loss of $138 million in 2025, which is an increase from a $68 million loss in 2024, attributed to rising research costs [10]. - The company has not yet generated sales, making future revenue dependent on the successful approval of its therapies [11]. Market Context - The stock reached a 52-week high of $20.25 shortly after Mazumdar's sale, driven by positive developments in clinical trials for ficerafusp alfa [10]. - The current market conditions suggest that while the stock price has risen, potential investors must weigh the risks of setbacks against the possibility of significant returns [11].

Core Insights - Bicara Therapeutics is advancing its lead asset, ficerafusp alfa, which has received Breakthrough Therapy Designation from the FDA for the treatment of metastatic or unresectable HPV-negative recurrent head and neck squamous cell carcinoma (HNSCC) [2][7] - The company has reported promising Phase 1b clinical data, indicating a median duration of response of 21.7 months and median overall survival of 21.3 months in a cohort receiving 1,500 mg weekly [6][8] - Bicara has successfully raised $161.8 million through an oversubscribed public offering, enhancing its financial position with $414.8 million in cash and equivalents as it prepares for pivotal trials and potential product launch [5][21] Clinical Development - The Phase 1b study involved approximately 90 patients and demonstrated tumor shrinkage across all doses, with deeper responses observed at higher exposure levels [6][10] - The company plans to implement a loading and maintenance dosing strategy, with the optimal biological dose set at 1,500 mg, and an interim analysis for the Phase III FORTIFY-HN01 study expected in mid-2027 [1][7] - Data from various dosing cohorts have informed the selection of the 1,500 mg weekly regimen as the optimal dose for the pivotal trial [9][11] Regulatory and Market Strategy - Bicara is on a path toward potential accelerated approval in the U.S. based on response-rate endpoints at interim analysis, while noting that full approval outside the U.S. may require overall survival data [16] - The company is also exploring a parallel study for a less frequent dosing regimen, with an estimated size of 150-200 patients, pending regulatory alignment [14] Financial Overview - Operating expenses are expected to rise in 2026 due to increased clinical operations and development costs, as well as expanded headcount to support commercial infrastructure [20] - The additional capital raised is intended to support regulatory filings, alternative dosing schedules, and early signal-finding work for potential indication expansion [21]

Q4 / FY 2025 Earnings Call March 30, 2026 © 2024 – 2026 Bicara Therapeutics Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding our strategy, business plans and focus; express or implied statements regarding the clinical development of ficerafusp alfa, including anticipated substantial enrollm ...

Core Insights - Bicara Therapeutics has selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial, with an interim analysis expected by mid-2027 [1][5] - The company announced a new dosing regimen for ficerafusp alfa, which includes a less frequent loading and every-three-week maintenance dose [1][5] - Bicara's CEO highlighted the company's strong momentum in clinical, regulatory, and corporate priorities, emphasizing the potential impact on patients with HPV-negative head and neck cancer [2] Clinical Development - The FORTIFI-HN01 trial is a pivotal Phase 2/3 study focusing on ficerafusp alfa for first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma [3] - Ongoing Phase 1b expansion cohorts are evaluating ficerafusp alfa both as a monotherapy and in combination with pembrolizumab for patients with third-line or greater metastatic colorectal cancer [3][7] - Data presented at various conferences indicated that ficerafusp alfa is well-tolerated and shows promising efficacy, supporting the higher dose selection [5] Financial Highlights - Bicara raised net proceeds of $161.8 million through an oversubscribed public offering, aimed at enhancing its medical and commercial infrastructure [4][6] - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $414.8 million, down from $489.7 million in 2024 [12] - Research and development expenses for Q4 2025 were $33.0 million, compared to $19.9 million in Q4 2024, reflecting increased costs associated with clinical trials [12] Upcoming Milestones - The company anticipates substantial enrollment in the FORTIFI-HN01 pivotal study by the end of 2026, enabling an interim analysis readout in mid-2027 [11] - Bicara plans to present long-term follow-up data from the Phase 1b study at the 2026 ASCO Annual Meeting [11] - The company aims to make critical commercial hires, including a Chief Commercial Officer, by the end of 2026 to prepare for potential product launch [11]

Company Overview - Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for patients with solid tumors [3] - The company's lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to enhance tumor penetration by addressing barriers in the tumor microenvironment [3] Upcoming Financial Results - Bicara Therapeutics will report its fourth quarter and full year 2025 financial results and business updates on March 30, 2026, before the market opens [1] - A conference call to discuss these results will be held at 8:30 a.m. ET on the same day [1] Product Details - Ficerafusp alfa combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) [3] - This targeted mechanism aims to reverse the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling, facilitating deeper and more durable responses in treatment [3] - The product is being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [3]

Summary of Bicara Therapeutics FY Conference Call Company Overview - Bicara Therapeutics focuses on bifunctional antibodies targeting tumors, specifically utilizing an EGFR TGF-beta mechanism to enhance treatment efficacy in cancer patients [1][2] - The company was founded in 2020 and licensed intellectual property from Biocon [1] Key Developments - Bicara has initiated a registrational trial for its lead program in recurrent metastatic head and neck cancer, with top-line data expected in mid-2027 [2] - The trial targets an HPV-negative population, historically considered immune excluded, where effective drug delivery has been challenging [5] Mechanism of Action - The synergy between EGFR and TGF-beta is emphasized, with higher levels of both proteins present in HPV-negative head and neck cancer patients [6] - TGF-beta is believed to help overcome acquired resistance mechanisms associated with EGFR, enhancing treatment effectiveness [8][12] Clinical Data - Early data presented at ASCO 2023 showed a 21% complete response rate at the 1500 mg dose, significantly higher than the historical 4%-7% complete response rate for Pembrolizumab (Pembro) [9][10] - The confirmed response rate in the same population was reported at 55%, with a median duration of response of 21.7 months [11] - The trial demonstrated deeper and more durable responses compared to existing therapies, indicating the potential of TGF-beta in enhancing treatment outcomes [12] Trial Design and Regulatory Strategy - The ongoing phase 3 trial is designed as a three-arm study, comparing ficerafusp alfa at two doses against Pembro monotherapy [40][42] - The trial aims for accelerated approval based on overall response rate (ORR) and will continue to follow patients for overall survival (OS) [44] - Approximately 600-650 patients will be enrolled, with a focus on ensuring a high degree of confidence in meeting the OS endpoint [52] Commercial Strategy - Bicara raised $172 million to build its commercial and medical affairs infrastructure, targeting a launch in the U.S. [74][76] - The company plans to leverage its understanding of the prescriber universe in head and neck cancer, which is relatively concentrated [76] Future Opportunities - Bicara is exploring additional indications for ficerafusp alfa beyond head and neck cancers, including colorectal cancer and locally advanced settings where TGF-beta levels are increased due to radiation [81][83] - The company is also developing a PCR HPV test for co-approval, which is expected to facilitate patient enrollment and reimbursement processes [71][73] Conclusion - Bicara Therapeutics is positioned to make significant advancements in the treatment of head and neck cancer through its innovative approach combining EGFR and TGF-beta mechanisms, with promising clinical data and a strategic plan for commercialization and further research into additional cancer types [1][2][81]

Core Insights - Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors [4] Group 1: Employee Inducement Grant - Bicara awarded a non-qualified stock option to a new employee, allowing the purchase of 115,000 shares at an exercise price of $17.59 per share, which matches the closing price on March 2, 2026 [2] - The stock options will vest over time, with one-fourth vesting on the first anniversary of the employee's start date and the remaining shares vesting in 12 equal quarterly installments, contingent on continued service [2][3] - This award was granted outside of Bicara's stockholder-approved equity incentive plans and is part of the 2026 Inducement Plan approved by the board of directors [3] Group 2: Company Overview - Bicara's lead program, ficerafusp alfa, is a first-in-class bifunctional antibody aimed at improving tumor penetration by addressing barriers in the tumor microenvironment [4] - Ficerafusp alfa targets both epidermal growth factor receptor (EGFR) and human transforming growth factor beta (TGF-β), reversing the fibrotic and immune-excluded tumor microenvironment [4] - The drug is being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [4]

Summary of Bicara Therapeutics FY Conference Call Company Overview - **Company**: Bicara Therapeutics (NasdaqGM:BCAX) - **Focus**: Development of bifunctional antibodies, specifically ficerafusp alfa, targeting EGFR and TGF-beta [2][3] Core Points and Arguments Product Development - **Lead Program**: Ficerafusp alfa is designed to overcome the limitations of TGF-beta delivery to tumors, particularly in head and neck cancer [2] - **Clinical Trials**: The FORTIFY trial for HPV-negative recurrent metastatic head and neck cancer was initiated in February 2025, with increasing enrollment and site activation [3][4] Clinical Data - **Response Rates**: Ficerafusp alfa demonstrated a confirmed overall response rate of 54%, with a complete response rate of 21% and a median time to response of 1.4 months [6][9] - **Duration of Response**: The median duration of response is reported at 21.7 months, significantly higher than other EGFR therapies [7][9] - **Survival Metrics**: The company aims to demonstrate a doubling of the control arm's response rate, with a target for overall survival (OS) improvement based on historical data [21][26] Market Potential - **Head and Neck Cancer Market**: The potential market for ficerafusp in head and neck cancer is estimated to exceed $5 billion, with current treatments showing low response rates (19%-36%) [4][42] - **Competitive Landscape**: Bicara believes it has a competitive edge over other therapies, such as amivantamab, due to better efficacy, safety, and a more convenient dosing schedule [46] Future Plans - **Commercial Strategy**: Bicara plans to build its commercial infrastructure in 2026, with a target launch in 2028 [15][14] - **Expansion into Other Indications**: The company is exploring ficerafusp in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), with data expected in the second half of 2026 [14][49] Additional Important Information - **FDA Interactions**: Bicara has received favorable feedback from the FDA regarding its dosing strategy, supporting the move to a 1,500 mg weekly dose [30][28] - **Enrollment Trends**: Approximately 60% of trial enrollment is expected to occur outside the U.S., with significant momentum in Europe and plans to expand into Asia and South America [18][17] - **TGF-beta Mechanism**: The drug's mechanism involving TGF-beta is expected to differentiate it from other treatments, potentially leading to better patient outcomes [27][12] This summary encapsulates the key points discussed during the conference call, highlighting Bicara Therapeutics' strategic focus, clinical advancements, market potential, and future directions.

Core Viewpoint - Bicara Therapeutics Inc. has successfully closed a public offering, raising approximately $172.5 million to support the development and commercialization of its lead therapy, ficerafusp alfa, aimed at treating solid tumors [1][2]. Group 1: Offering Details - The company offered 8,581,250 shares of common stock and pre-funded warrants for 2,200,000 shares at an exercise price of $0.0001 per share [1]. - The public offering price was set at $16.00 per share for common stock and $15.9999 for pre-funded warrants [1]. - The offering included an option exercised in full by underwriters for an additional 1,406,250 shares [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to build medical and commercial infrastructure for a planned regulatory filing and commercial launch of ficerafusp alfa in the U.S. [2]. - Funds will also accelerate the development of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule [2]. - Additional uses include covering manufacturing costs for ongoing drug development, early signal-finding for future indication expansion, and general corporate purposes [2]. Group 3: Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors [6]. - The lead program, ficerafusp alfa, is designed to enhance tumor penetration by targeting the tumor microenvironment, combining an EGFR-directed monoclonal antibody with a TGF-β binding domain [6]. - The therapy aims to address significant unmet needs in head and neck squamous cell carcinoma and other solid tumor types [6].

Core Viewpoint - Bicara Therapeutics Inc. has announced a public offering of 7,175,000 shares at $16.00 per share, aiming to raise approximately $150 million to support its clinical and commercial initiatives for ficerafusp alfa, a bifunctional therapy for solid tumors [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for 2,200,000 shares at a price of $15.9999 each, with gross proceeds expected to be around $150 million before expenses [1]. - The offering is set to close on or about February 26, 2026, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 1,406,250 additional shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds will be used to enhance medical and commercial infrastructure for a planned regulatory filing and launch of ficerafusp alfa in the U.S. [2]. - Funds will also support the development of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule [2]. - Additional uses include covering manufacturing costs for ongoing drug development and early signal-finding for future indication expansion [2]. Group 3: Company Overview - Bicara Therapeutics is focused on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, designed to penetrate tumors by overcoming barriers in the tumor microenvironment [6]. - Ficerafusp alfa combines an EGFR-directed monoclonal antibody with a domain that binds to TGF-β, aiming to reverse the fibrotic and immune-excluded tumor microenvironment [6]. - The therapy is being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [6].